Editorial, J Bioeng Med Technol Vol: 5 Issue: 3

AI-Powered Radiogenomics: Integrating Imaging and Genomics for Precision Medicine

Dr. Hana M. Takahashi^*

Dept. of Medical Imaging Technology, Kyoto Frontier University, Japan

*Corresponding Author:

Dr. Hana M. Takahashi
Dept. of Medical Imaging Technology, Kyoto Frontier University, Japan
E-mail: h.takahashi@kfu.jp

Received: 01-Sep-2025, Manuscript No. jbmt-26-185019; Editor assigned: 4-Sep-2025, Pre-QC No. jbmt-26-185019 (PQ); Reviewed: 18-Sep-2025, QC No. jbmt-26-185019; Revised: 25-Sep-2025, Manuscript No. jbmt-26-185019 (R); Published: 30-Sep-2025, DOI: 10.4172/jbmt.1000094

Citation: Hana MT (2025) AI-Powered Radiogenomics: Integrating Imaging and Genomics for Precision Medicine. J Bioeng Med Technol 5: 094

Abstract

Introduction

Modern medicine increasingly relies on both advanced imaging technologies and genomic profiling to diagnose and manage disease. Radiology provides noninvasive visualization of anatomical structures and functional processes, while genomics reveals the molecular and genetic characteristics underlying disease behavior. Traditionally, these domains have operated independently. AI-powered radiogenomics seeks to bridge this gap by using artificial intelligence to uncover relationships between imaging features and genetic information [1,2].

Radiogenomics is the study of correlations between radiographic imaging traits and gene expression patterns, mutations, or molecular subtypes. By applying machine learning and deep learning techniques to large imaging and genomic datasets, researchers can identify hidden patterns that may not be visible to the human eye. This integrated approach holds significant promise for advancing precision medicine, particularly in oncology [3,4].

Discussion

AI plays a central role in extracting quantitative features from medical images such as MRI, CT, and PET scans. These features, often referred to as radiomic features, include texture, shape, intensity, and spatial relationships within tumors or tissues. Machine learning algorithms analyze these high-dimensional data and link them with genomic profiles derived from tumor biopsies or sequencing technologies [5].

In cancer research, AI-powered radiogenomics has demonstrated the potential to predict genetic mutations and molecular subtypes noninvasively. For example, specific imaging patterns may correlate with mutations that influence tumor aggressiveness or response to targeted therapies. This capability could reduce the need for repeated biopsies, which are invasive and sometimes impractical due to tumor location or patient condition. Additionally, radiogenomic models can assist in treatment planning by predicting therapy response or disease progression based on imaging-genomic signatures.

Beyond oncology, radiogenomics may support applications in neurological disorders, cardiovascular disease, and inflammatory conditions. By linking imaging biomarkers with molecular pathways, clinicians can gain a more comprehensive understanding of disease mechanisms. Integration with clinical data and electronic health records further enhances predictive modeling, supporting individualized treatment strategies.

However, several challenges remain. Large, high-quality datasets that combine standardized imaging and genomic information are essential for reliable model development. Variability in imaging protocols, data privacy concerns, and the need for explainable AI models are ongoing considerations. Regulatory approval and clinical validation are also critical steps before widespread adoption.

Conclusion

AI-powered radiogenomics represents a transformative convergence of imaging science, genomics, and artificial intelligence. By revealing hidden associations between visual and molecular characteristics of disease, it offers a powerful tool for noninvasive diagnosis, risk assessment, and personalized therapy planning. Although technical and ethical challenges persist, continued advancements in data integration and machine learning are accelerating progress. In the future, radiogenomics may become a cornerstone of precision medicine, enabling more accurate, efficient, and individualized healthcare.

References

1. Pandey S, Gupta K, Mukherjee AK (2007) Impact of cadmium and lead on Catharanthus roseus - A phytoremediation study. Journal of Environmental Biology 28: 655-662.

   Indexed at, Google Scholar

2. Ahmad NH, Rahim RA, Mat I (2010) Catharanthus roseus aqueous extract is cytotoxic to Jurkat leukemic T-cells but induces the proliferation of normal peripheral blood mononuclear cells. Tropical Life Science Research 21: 101-113.

   Indexed at, Google Scholar, Crossref

3. Subhashini V, Swamy AVVS (2013) Phytoremediation of Pb and Ni Contaminated Soils Using Catharanthus roseus (L.). Universal Journal of Enviromental Research and Technology 3:465-472.

   Indexed at, Google Scholar, Crossref

4. Nayak BS (2007) Evaluation of woundhealing potential of Catharanthus roseus leaf extract in rats. Phytotherapies 78.7-8: 540-544.

   Indexed at, Google Scholar, Crossref

5. SV, Sain M (2013) Catharanthus roseus (An Anticancerous Drug Yielding Plant) - A Review Of Potential Therapeutic Properties. International Journal of Pure and Applied Bioscience 139-42.

   Google Scholar